PuSH - Publication Server of Helmholtz Zentrum München: Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Patil, S.* ; Linge, A.* ; Grosser, M.* ; Lohaus, F.* ; Gudziol, V.* ; Kemper, M.* ; Nowak, A.* ; Haim, D.* ; Tinhofer, I.* ; Budach, V.* ; Guberina, M.* ; Stuschke, M.* ; Balermpas, P.* ; Rödel, C.* ; Schäfer, H.* ; Grosu, A.L.* ; Abdollahi, A.* ; Debus, J.* ; Ganswindt, U.* ; Belka, C. ; Pigorsch, S.* ; Combs, S.E. ; Boeke, S.* ; Zips, D.* ; Baretton, G.B.* ; Baumann, M.* ; Krause, M.* ; Löck, S.*

Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.

Radiother. Oncol. 171, 91-100 (2022)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

PURPOSE: The aim of this study was to develop and validate a novel gene signature from full-transcriptome data using machine-learning approaches to predict loco-regional control (LRC) of patients with human papilloma virus (HPV)-negative locally advanced head and neck squamous cell carcinoma (HNSCC), who received postoperative radio(chemo)therapy (PORT-C). MATERIALS AND METHODS: Gene expression analysis was performed using Affymetrix GeneChip Human Transcriptome Array 2.0 on a multicentre retrospective training cohort of 128 patients and an independent validation cohort of 114 patients from the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Genes were filtered based on differential gene expression analyses and Cox regression. The identified gene signature was combined with clinical parameters and with previously identified genes related to stem cells and hypoxia. Technical validation was performed using nanoString technology. RESULTS: We identified a 6-gene signature consisting of four individual genes CAV1, GPX8, IGLV3-25, TGFBI, and one metagene combining the highly correlated genes INHBA and SERPINE1. This signature was prognostic for LRC on the training data (ci=0.84) and in validation (ci=0.63) with a significant patient stratification into two risk groups (p=0.005). Combining the 6-gene signature with the clinical parameters T stage and tumour localisation as well as the stem-cell marker CD44 and the 15-gene hypoxia-associated signature improved the validation performance (ci=0.69, p=0.001). CONCLUSION: We have developed and validated a novel prognostic 6-gene signature for LRC of HNSCC patients with HPV-negative tumours treated by PORT-C. After successful prospective validation the signature can be part of clinical trials on the individualization of radiotherapy.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

6.901

0.000